Blog
RSS FeedPosted by Michael Wonder on 30 Mar 2023
Expanded access to subsidised oral antiviral Paxlovid and other COVID-19 supports
30 March 2023 - From 1 April, more than 160,000 people aged 60 to 69 will have access to the ...
Posted by Michael Wonder on 27 Mar 2023
COVID-19 vaccine safety report (23 March 2023)
23 March 2023 - To 19 March 2023, more than 44 million doses have been administered in Australia, as well ...
Posted by Michael Wonder on 22 Mar 2023
Drug repurposing during the COVID-19 pandemic: lessons for expediting drug development and access
20 March 2023 - The COVID-19 pandemic created a large, sudden unmet public health need for rapid access to safe and ...
Posted by Michael Wonder on 22 Mar 2023
Moderna expects to price its COVID vaccine at about $130 in the US
20 March 2023 - Moderna expects to price its COVID-19 vaccine at around $130 per dose in the US going ...
Posted by Michael Wonder on 15 Mar 2023
FDA authorises bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
14 March 2023 - Today, the US FDA amended the emergency use authorisation of the Pfizer-BioNTech COVID-19 vaccine, bivalent to provide ...
Posted by Michael Wonder on 11 Mar 2023
COVID-19 vaccine safety report (9 March 2023)
9 March 2023 - To 5 March 2023, over 44 million doses have been administered in Australia, as well as about ...
Posted by Michael Wonder on 09 Mar 2023
Swissmedic issues unlimited authorisation for booster dose of Moderna's bivalent COVID-19 Original/Omicron BA.4-5 vaccine
8 March 2023 - Spikevax bivalent Original/Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over. ...
Posted by Michael Wonder on 01 Mar 2023
Pfizer and BioNTech submit for US emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 booster in children under 5 years
1 March 2023 - Pfizer and BioNTech today submitted an application to the US FDA for emergency use authorisation of ...
Posted by Michael Wonder on 01 Mar 2023
Release of the Australian Government's response to the Review of COVID-19 Vaccine and Treatment Purchasing and Procurement
28 February 2023 - The Australian Government has responded to the Halton review into COVID-19 vaccine and treatment procurement. ...
Posted by Michael Wonder on 01 Mar 2023
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
28 February 2023 - Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent ...
Posted by Michael Wonder on 28 Feb 2023
Supplies secured of latest Moderna COVID-19 vaccine as recommended by Halton Review
28 February 2023 - The Australian Government has secured an additional 3 million doses of the latest Moderna Omicron-specific COVID-19 vaccine ...
Posted by Michael Wonder on 27 Feb 2023
Pfizer and BioNTech submit supplemental biologics license application for US FDA approval of Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine for ages 12 years and older as primary series or booster
24 February 2023 - Pfizer and BioNTech today announced they have submitted a supplemental biologics license application to the US ...
Posted by Michael Wonder on 24 Feb 2023
Merck and Ridgeback provide update on EU marketing authorisation application for Lagevrio (molnupiravir)
24 February 2023 - Merck and Ridgeback Biotherapeutics today announced that the CHMP of the EMA has recommended the refusal ...
Posted by Michael Wonder on 23 Feb 2023
COVID-19 vaccine safety report (23 February 2023)
23 February 2023 - To 19 February 2023, over 44 million doses have been administered in Australia, as well as ...
Posted by Michael Wonder on 23 Feb 2023
Vir Biotechnology announces positive final draft guidance on sotrovimab from the UK’s NICE
22 February 2023 - Final draft guidance based on cost effectiveness evaluation of sotrovimab. ...